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ARTICLE OPEN
A primary care database study of asthma among patients
with and without opioid use disorders
Phillip Oliver 1✉, Joe Hulin 2 and Caroline Mitchell 1
Substance misuse is associated with poor asthma outcome and death. People with opioid use disorder (OUD) may be at particular
risk, however, there have been no case-control studies of asthma care and outcomes in this patient group. A primary care database
study of patients with asthma aged 16–65 years was conducted using a matched case-control methodology. The dataset comprised
275,151 adults with asthma, of whom 459 had a clinical code indicating a lifetime history of OUD. Cases with a history of OUD were
matched to controls 1:3 by age, gender, smoking status and deprivation index decile. Attendance at annual review (30%) and for
immunisation (25%) was poor amongst the overall matched study population (N= 1832). Compared to matched controls, cases
were less likely to have attended for asthma review during the previous 12 months (OR= 0.60, 95% CI 0.45–0.80) but had similar
immunisation rates. Higher rates of ICS (OR= 1.50, 1.13–1.98) and oral prednisolone use (OR= 1.71, 1.25–2.40) were seen amongst
those with a history of OUD and 7.2% had a concurrent diagnosis of COPD (OR= 1.86, 1.12–2.40). We found that people with
asthma and a history of OUD have worse outcomes on several commonly measured metrics of asthma care. Further research is
required to identify reasons for these findings, the most effective strategies to help this vulnerable group access basic asthma care,
and to better understand long-term respiratory outcomes.
npj Primary Care Respiratory Medicine           (2020) 30:17 ; https://doi.org/10.1038/s41533-020-0174-2
INTRODUCTION
Asthma is amongst the most common long-term health condi-
tions in the UK1 and represents a significant burden for patients,
general practice, emergency medicine and secondary care. Small
scale observational studies suggest that people with asthma and
opioid use disorder (OUD) experience high rates of acute
exacerbations2, have more severe symptoms during acute
episodes3,4 and are more likely to need intensive care treatment
and intubation5,6. The UK has one of the highest rates of death
from asthma in Europe7 and in the 2014 UK National Review of
Asthma Deaths, substance misuse was identified as a factor in 6%
of the cases8. Supported self-management such as medication
adherence9, attendance at asthma review10,11 and immunisation12
are known to improve outcome. However, people with substance
use disorders (SUD) often live with significant psychosocial
challenges, for example poverty, stigma, family breakdown,
insecure housing and incarceration, which may affect their access
to healthcare services13.
Lack of healthcare utilisation may explain why outcomes
amongst people with asthma and SUD appear to be so poor,
but the nature of specific illicit drug use might also be a significant
additional factor for those with OUD. As a part of the harm
minimisation paradigm, injecting heroin users were encouraged
to adopt alternative routes of drug use and by the late 1990s,
inhalation became a common method of administration in many
countries14,15. These ‘route transition interventions’ were aimed at
reducing the risk of fatal overdose, blood-borne virus transmission
and intravenous drug injection-associated infections. However,
inhalation of heroin has bronchoconstrictive effects in the lungs3,
probably mediated by the ability of morphine to cause histamine
release16, and appears to contribute to progressive irreversible
lung disease, such as emphysema and chronic obstructive
pulmonary disease (COPD)17,18. Assessing the contribution of
inhalation of opioids to lung outcomes is challenging as the vast
majority of those with SUD smoke tobacco19. It is known that
people with SUD have significantly higher excess mortality than
the general population from causes, including cancer, cardiovas-
cular and respiratory disease20, and it is likely that a significant
proportion of this excess mortality is explained by tobacco
smoking.
At present, there is little existing research that has attempted to
quantify asthma outcomes among people with OUD. The majority
of existing research comes from small scale and case-series data17.
More generally, it is recognised that the literature on the
pulmonary consequences of heroin use is scant18. When assessing
asthma outcomes amongst people with OUD, it is important to
acknowledge this group are more likely to be male, come from
areas of high deprivation and have smoking histories5. Factors
such as these have been shown to influence asthma outcomes
including exacerbation rates21–24. This study, aims to assess
asthma care and outcomes amongst asthma patients with a
history of OUD in a large primary care population after controlling
for such confounding.
RESULTS
Rates of OUD
In all, 275,151 patients aged 16–65 years with asthma were
identified from the ResearchOne database. Of these, 459 had a
clinical code indicating past or current OUD. Of the total number
of patients, 254,568 had complete data available for matching
(Fig. 1). There was no difference in the frequency of historical OUD
between those with complete and those with missing data
(Pearson χ2= 1.346, p= 0.246).
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Study population characteristics—matched groups
Comparison between the groups with respect to demographics
and smoking history are shown in Table 1 along with the results of
significance tests. As expected, statistically significant differences
with respect to the measured confounding factors were seen.
Whilst asthma patients with a history of OUD were only slightly
older, they were much more likely to be male and considerably
more likely to live in an area with the highest level of deprivation.
Ninety five percent of those with a history of OUD had a history of
smoking compared to 52% of non-opioid users.
Outcomes—descriptive statistics
After matching, the analysis population comprised 458 asthma
patients with a history of past or current OUD (cases) and 1374
without (controls). Table 2 gives values and percentages for each
of the outcome variables. Less than one third of the study sample
had attended for an asthma review in the previous 12 months,
with those in the control group more likely to have attended than
cases (31% vs. 26%). More than three quarters of all patients had
not received an influenza vaccination during the observation
period with marginally higher rates of uptake amongst the control
group (25% vs. 23%). Asthma patients from the control group
were less likely to have been issued three or more corticosteroid
containing inhalers (29% vs. 36%) in the previous 12 months with
overall rates for both groups of 31%. Approximately 8% of the
1832 patients received a prescription for oral prednisolone on at
least one occasion in the 12-month period with cases recorded as
having double the rates of controls (12 vs. 6%). The overall
prevalence of COPD amongst the study group was 4.5% with
higher rates recorded for those with a history of OUD compared to
controls (7.2% vs. 3.6%).
Outcomes—odds ratios estimated from conditional logistic
regression
Crude and adjusted odds ratios (ORs) with 95% confidence
intervals (CIs) for all outcome variables are shown in Table 3.
Statistically significant ORs were found for all outcomes other than
receiving an influenza vaccination (95% CI 0.68–1.14). The
adjusted odds of attending for an asthma review were around
40% lower for cases than controls (95% CI 0.45–0.80) whereas the
adjusted odds of receiving three or more ICS inhalers (95% CI 1.13
to 2.98), being issued a prescription for oral prednisolone (95% CI
1.25–2.34), or having a pre-existing diagnosis of COPD (95% CI
1.12–3.01) were increased by 50%, 71% and 86% respectively.
Crude and adjusted odds ratios were similar suggesting that there
were no significant interactions between the outcome variables
other than for co-existing COPD in which the adjusted OR fell from
2.26 to 1.86.
DISCUSSION
Our findings confirm that asthma patients with evidence of
previous OUD are more likely to be older, male, come from areas
of higher deprivation and have a smoking history. Ignoring, for a
moment the role of OUD, we found low rates of access to asthma
care and inhaled ICS prescriptions amongst both cases and
controls. In matched analyses, opioid users were less likely to
attend for annual review but had higher rates of ICS prescriptions.
Asthma patients with a history of OUD use had higher rates of oral
prednisolone use within the previous 12 months and were more
likely to have a co-existing clinical code for COPD. The latter was
the only variable, which appeared to be influenced by other
outcomes in multi-variable analyses.
Supported self-management forms the cornerstone of asthma
treatment and has been shown to reduce hospital admission and
unscheduled clinical contacts25. It was therefore, striking to find
such low rates of achievement of the quality indicators for asthma
care in this study. Less than one third of the 1832 patients had
attended for an asthma review in the past 12 months and less
Paents aged 16–65 
with asthma 
275,151 
Paents available 
for analysis 
254,568 
Opioid use history 
(cases) 
459 
No opioid use history 
(control populaon) 
254,109 
Case group 
458 
Matching 1:3 (age, gender, 
smoking history and IMD) 
Missing data: 
IMD 17,580 
Gender 3 
Control group 
1374 
Fig. 1 Matched case-control methodology. Flow diagram showing
process by which case and control groups were derived from the
dataset. IMD index of multiple deprivation.
Table 1. Study population characteristics.
History of opioid use No history of opioid use Significance tests
Total (%) 459 (0.18%) 254,109 (99.82%)
Mean age (SD) 39.9 years (8.4) 38.4 years (13.8) Mean difference (95% CI)
1.53 years (0.27–2.8), p= 0.018a
% Female 38.8 51.3 χ2= 28.16, p < 0.001
% Smoking history 94.8 52.0 χ2= 335.83, p < 0.001
% in most deprived IMD centile 37.5 10.9 χ2= 330.50, p < 0.001
aIndependent groups t-test, two-tailed p value.
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than a quarter had received an influenza vaccination. This is
despite these aspects of asthma care being incentivised in
England through the Quality Outcomes Framework (QoF) and
the Enhanced Services Specification26, respectively. The rates of
attendance an asthma review in our matched sample were
considerably lower than the rates among the UK general
population of asthma patients in similar database. For example,
in a recent study using the Clinical Practice Research Datalink
(CPRD) (an alternative UK GP database to ResearchOne), 43.7% of
patients had attended for asthma review27. After controlling for
measured confounding and other outcomes variables, we found
that OUD was associated with a 40% reduction in the odds of
having attended for asthma review. The finding of higher rates of
ICS prescriptions among those with a history of OUD is somewhat
at odds with this and has several possible interpretations.
Assuming that both groups have similar severity of asthma
requiring regular ICS-preventer therapy, then, taken at face value,
this suggests higher adherence amongst those with a history of
OUD. In the context of other chronic health conditions such as HIV,
medication adherence is known to be lower in those with SUD28
and so this would seem unlikely. An alternative explanation is that
clinical need for an ICS-containing inhaler was different between
the two groups and the higher OR is a reflection of this rather than
differences in adherence per se. This would be consistent with the
notion that OUD is associated with poorer lung function in those
with asthma. It is also known that use of ICS increases during the
period before and after exacerbations29, which could also explain
the direction of this outcome. A national sample of data from the
CPRD reported by Bloom et al., indicate that around 65% of
people with asthma aged 18–54 years received ≥3 ICS inhalers in
201627. Therefore, irrespective of the interpretation of the
differences between those with a history of OUD and their
matched counterparts, the rates of ICS prescriptions seen in this
study as well as attendance at asthma review are worryingly low.
In a systematic review of strategies for implementing supported
self-management for people with asthma11, Pinnock and collea-
gues found that that a whole system approach, targeting patients,
professionals and organisations was crucial to improving global
asthma care outcomes and that effective interventions were
characterised by multi-faceted proactive care. These authors also
call for further research into how whole system approaches can be
integrated into the routine care of people with asthma and
comorbidities as well demographically diverse groups11.
There is consensus that the definition of asthma exacerbation
should include the systemic use of oral corticosteroids (OCS)30 and
prescriptions for oral prednisolone have previously been used as a
measure of exacerbation from database studies27,31. The present
study findings, suggest that OUD is associated with increased
rates of asthma exacerbations. In addition to the acute risks,
asthma exacerbations are independent predictors of future
exacerbation32 and are correlated with the irreversible airflow
limitations over time33. There is increasing evidence that
inhalation of opioids results in airways disease and in a recent
screening study, Burhan et al.34 found that most heroin smokers
screened in a community setting showed evidence of spirometry-
confirmed COPD or COPD-asthma overlap. The present study
complements this work as it demonstrates that asthma patients
with a history of opioid use have greater rates of COPD
independent of some of the main risk factors for the development
of this condition, namely tobacco smoking history, deprivation
and age35. Concurrent diagnoses of asthma and COPD are
associated with higher all-cause mortality36 and our results
suggest that asthma patients with a history of OUD are almost
twice as likely to have a comorbid diagnosis of COPD. The odds
ratio in our multivariable (adjusted) analysis for the presence of a
COPD diagnosis was lower than in the univariate analysis. One
tentative interpretation of this is that reducing exacerbations and/
or improving engagement with self-supported care could
influence the development of COPD. Further research could
explore this possibility by replicating this work in alternative
primary care databases.
Clinical recording systems such as ResearchOne and similar
databases are widely used and validated for asthma epidemiolo-
gical research37. However, it is known that substance use is under-
recorded in primary care databases38. In the present study, only
0.2% of those with a history of asthma were identified as also
having a clinical code associated with OUD. The decisions taken
by primary care physicians to record substance use are complex39
and therefore it is necessary to be cautious in generalising the
present results. As this was a database study, it was also not
possible to determine current OUD and the findings therefore
relate to a lifetime history which may include both current and
past OUD. We chose not to omit those who did not have evidence
Table 3. Crude and adjusted odds ratios and 95% CIs from conditional logistic regression analysis.
Outcome (previous 12 months) Crude OR (95% CI) P-valuea Adjustedb OR (95% CI) P-valuea
Attended for asthma review 0.756 (0.591–0.968) 0.026 0.600 (0.449–0.801) 0.001
Received influenza immunisation 0.878 (0.677–1.139) 0.328 0.796 (0.594–1.067) 0.127
≥3 issued prescriptions for an ICS inhaler 1.357 (1.077–1.708) 0.009 1.497 (1.131–1.982) 0.005
Issued prescription for oral prednisolone 1.779 (1.337–2.367) <0.001 1.708 (1.247–2.339) 0.001
Existing clinical code for COPD 2.226 (1.371–3.613) 0.001 1.863 (1.120–3.098) 0.017
OR odds ratio, ICS inhaled corticosteroid, COPD chronic obstructive pulmonary disease.
aWald test.
bAdjusted for all other outcomes variables in column 1.
Table 2. Outcome variables—study population (N= 1832).
Outcome (past
12 months)
History of
opioid use
(cases)
n= 458
No history of
opioid use
(controls)
n= 1374
All
N= 1832
Number
%
Number
%
Number
%
Attended for
asthma review
118 427 545
25.8% 31.1% 29.7%
Received influenza
vaccination
105 345 450
22.9% 25.1% 24.6%
≥3 issued prescriptions
for an ICS inhaler
161 402 565
35.6% 29.3% 30.8%
Issued prescription for
oral prednisolone
57 84 141
12.4% 6.1% 7.7%
Existing clinical code
for COPD
33 50 83
7.2% 3.6% 4.5%
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of active asthma, such as prescription issues within an arbitrary
timeframe and did not examine exception reporting (a process by
which a patient may be ‘excepted’ from the targets set in a
particular clinical area of the QOF on certain grounds or informed
dissent). This was done in an attempt to avoid a potential source
of selection bias. There are several potential undesirable
consequences of this. Firstly, it is possible that the overall low
rates of measured outcomes were simply due to some patients
having resolved asthma but with their Read Code not appro-
priately removed. Secondly, patients may have poorer engage-
ment in part because they have been exception reported. This
could potentially explain some of the differences seen between
the cases and controls from this study. With respect to ICS use,
although our method was pre-specified, a more formal measure of
adherence such as the Annual Prescription Possession method
may have been desirable to aid comparison with existing
literature. Some qualification is also required with respect to
matching. As only a basic measure of tobacco smoking history was
used (absence or presence) it possible that those with a history of
OUD were heavier smokers than those without such histories.
More generally, as this is an observational study, there may have
been detrimental exposures in the OUD group which were not
measured.
Taken together, the results of this study suggest that people
with OUD have poor access to asthma care/self-management and
worse outcomes on several important measures, despite control-
ling for important factors which are known to have deleterious
effects on asthma, such as tobacco smoking and lower socio-
economic status. Those with a history of OUD encounter a
complex range of negative determinants of health at a patient,
provider and health system level in common with patients from
other populations such as those with severe mental health
problems. Further research is required to identify reasons for poor
asthma care amongst those from vulnerable and marginalized
populations at a whole system level and to better understand how
OUD affects long-term respiratory outcomes.
METHODS
Data source
Data came from the ResearchOne clinical research database40, which
contains pseudo-anonymised pooled data from participating General
Practices in England, UK which use the System One clinical recording
system. The database contains information from the patient’s electronic
health record including coded clinical entries called Read codes (the
hierarchical clinical terminology system used by UK General Practices41)
and prescribing data. Research ethics approval was granted from North
West—Greater Manchester East Research Ethics committee on 12 January
2016 (16/NW/0037). Data were requested in the form of Read codes and
British National Formulary (BNF) chapter heading codes. The observation
period was the 12 months prior to the 8 October 2016.
Study design, population and outcome measures
A matched case-control study was conducted to examine differences
between asthma patients with and without a history of OUD. The study
population consisted of patients in ResearchOne-linked practices with
specific Read codes indicating a possible diagnosis of asthma. A Read code
list for this purpose (shown in Supplementary Table 1) was compiled
following consultation with a public health specialist. This method has
previously been shown to have a high positive predictive value for the
diagnosis of asthma42. Patients were eligible for inclusion if they were aged
16–65 years. Individuals with a history of OUD (cases) were identified using
the Read code list shown in Supplementary Table 2. As it is not possible to
ascertain current vs. past OUD (or OUD in remission), ‘history’ here refers to
lifetime history of OUD.
Variables of interest were selected to assess important aspects of asthma
care and outcomes. Asthma care measures were based on the British
Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/
SIGN) British Guidelines on the management of asthma43. These were:
attendance at annual asthma review; receiving an influenza vaccination
and being issued three or more prescriptions for a corticosteroid (ICS)-
containing inhaler as preventer therapy. The cut-off of three ICS-containing
inhalers was selected as providing the minimum number of inhalers in
order to achieve an approximate 80% adherence for a typical 200-metered
dose inhaler at two puffs per day. Annual asthma reviews, in the UK, are
structured consultations between a patient and, usually, a nurse, with the
aim of assessing current control of symptoms and important aspects of
self-management. These are recommended in the UK national guidelines
and are a NICE Quality and Outcomes Framework indicator1.
In addition, as a proxy measure of acute asthma exacerbation, we
examined whether any prescriptions of oral prednisolone had been issued
over the 12-month period. In order to minimise the chances of selecting
prednisolone prescribed for alternative indications such as rheumatologi-
cal conditions, we selected only 5 mg tablet issues with quantities which
would correspond to a 5 to 7-day course of 30–40mg. There is increasing
recognition of overlap between asthma and chronic obstructive pulmon-
ary disease (COPD)44. Progression of asthma to COPD may be driven, in
part, by exacerbations45 and there is evidence of an association between
heroin inhalation and the early development of emphysema46. We,
therefore, sought to explore this further by including comorbid diagnoses
of COPD. Comorbid diagnoses of COPD were identified through the
selection of appropriate Read codes shown in Supplementary Table 3.
Matching
Cases and controls were matched 1:3 on four confounding variables: age
(within 3 years), gender, any recorded smoking history and socioeconomic
status (SES). Multiple controls allow for increased statistical power and
whilst there is a general consensus that increasing the case-to-control ratio
above 1:4 results in very little gain in efficiency, some authors have argued
for greater ratios under certain circumstances47. The trade-off for this
however is that there may be a reduction in the overall matched sample
size. In the present study, a 1:3 ratio resulted in the loss of only one case
and was therefore chosen as the best compromise between statistical
efficiency and matched sample size. The English 2010 Index of Multiple
Deprivation (IMD) was used as the SES measure for this study. The IMD
contains 38 indicators, organised across seven domains of deprivation
which are combined to calculate an overall score representing the degree
of deprivation experienced by people living in an area48. The IMD score
associated with the patient’s last known address during the observation
period was used and converted to deciles for the purpose of matching.
Statistical analyses
Differences between asthma patients with and without a history of OUD
with respect to the matching variables were made for illustrative purposes.
Proportions were assessed using chi-squared tests and mean differences in
age were assessed with 95% confidence intervals and a two-tailed
independent group’s t-test. Adjusted and unadjusted (crude) odds ratios
and 95% confidence intervals were calculated using conditional logistic
regression49. All analyses and data handling were conducted using SPSS
version 24. Matching was conducted using the SPSS Python Essentials
case-control matching module.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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